Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes

被引:11
|
作者
Walraven, Iris [1 ,2 ,3 ]
Mast, M. Ruth [1 ,4 ]
Hoekstra, Trynke [1 ,2 ]
Jansen, Aaltje P. D. [1 ,5 ]
Rauh, Simone P. [1 ,2 ]
Rutters, Femke R. [1 ,2 ]
van der Heijden, Amber A. W. A. [5 ]
Elders, Petra J. M. [1 ,5 ]
Moll, Annette C. [1 ,3 ]
Polak, Bettine C. P. [1 ,3 ]
Dekker, Jacqueline M. [1 ,2 ]
Nijpels, Giel [1 ,5 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, NL-1007 MB Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Clin Pharmacol & Pharm, NL-1007 MB Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Gen Practice & Elderly Care Med, NL-1007 MB Amsterdam, Netherlands
关键词
cardiovascular mortality; hypertension; latent class growth modelling; microvascular complications; type 2 diabetes mellitus; MICROVASCULAR COMPLICATIONS; VASCULAR-DISEASE; RISK-FACTORS; MANAGEMENT; TRAJECTORIES; HYPERTENSION; MORTALITY; ASSOCIATION; RETINOPATHY; GUIDELINES;
D O I
10.1097/HJH.0000000000000680
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aims:In order to eventually improve blood pressure (BP) management, the aim of this study was to identify subgroups of type 2 diabetes mellitus (T2DM) patients with distinct trajectories of SBP levels. Identifying subgroups with distinct SBP trajectories helps to better understand the course of SBP levels in T2DM patients and its associated consequences. Subgroup characteristics were determined and the prevalence of complications and mortality rates over time in the different subgroups was investigated.Methods:Five thousand, seven hundred and eleven T2DM patients with at least two SBP follow-up measurements were selected from a prospective T2DM cohort of 9849 T2DM patients. The mean follow-up period was 5.7 years (range 2-9 years). Latent Class Growth Modeling, as currently the most flexible cluster analysis available, was performed to identify subgroups of patients with distinct SBP trajectories. Subgroup characteristics were determined by multinomial logistic regression analyses.Results:Four subgroups with distinct SBP trajectories were identified. The largest subgroup (85.6%) showed adequate SBP control (at or around 140mmHg) over time. The second subgroup (5.6%) were hypertensive in the first years, responded slowly to BP management and eventually reached SBP control. The third subgroup (3.4%) showed deteriorating hypertension during the first 4 years, then showed insufficient response to BP management. The fourth subgroup (5.4%) showed deteriorating hypertension over time. Patients within subgroups 2-4 were significantly older, comprised more women, used more antihypertensive medication and had a higher prevalence of retinopathy, microalbuminuria and cardiovascular disease (CVD) mortality.Conclusion:More than 85% reached and maintained adequate SBP control. Subgroups with a more unfavourable course of SBP control also showed higher rates of microvascular complications and CVD mortality over time. This study identified important subgroups to target in order to improve BP management in T2DM patients.
引用
收藏
页码:2091 / 2098
页数:8
相关论文
共 50 条
  • [31] Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
    Blonde, Lawrence
    Meneghini, Luigi
    Peng, Xuejun Victor
    Boss, Anders
    Rhee, Kyu
    Shaunik, Alka
    Kumar, Supriya
    Balodi, Sidhartha
    Brulle-Wohlhueter, Claire
    McCrimmon, Rory J.
    DIABETES THERAPY, 2018, 9 (03) : 1347 - 1358
  • [32] REAL WORLD IMPACT OF BLOOD PRESSURE CHANGES ON MORBIDITY AND MORTALITY IN TYPE 2 DIABETES
    Martinez, Fernando
    Miguel Calderon, Jose
    Sauri, Inmaculada
    Fernandez, Antonio
    Diaz, Javier
    Bea, Carlos
    Redon, Josep
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E186 - E186
  • [33] REAL WORLD IMPACT OF BLOOD PRESSURE CHANGES ON MORBIDITY AND MORTALITY IN TYPE 2 DIABETES
    Martinez, Fernando
    Miguel Calderon, Jose
    Sauri, Inmaculada
    Fernandez, Antonio
    Diaz, Javier
    Bea, Carlos
    Redon, Josep
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL 1) : E186 - E186
  • [34] PREDICTORS OF SUCCESS AND FAILURE IN ACHIEVING GLYCEMIC CONTROL TARGETS IN PATIENTS WITH TYPE 2 DIABETES ON BASAL INSULIN: REVIEW OF THE REAL-WORLD EVIDENCE STUDIES
    Klimontov, Vadim V.
    DIABETES MELLITUS, 2022, 25 (06): : 556 - 563
  • [35] Proportion of IBD patients with suboptimal control in daily clinical practice - real-world evidence from the IBD Podcast study
    Dignass, A.
    D'Amico, F.
    Gomollon, F.
    Bamias, G.
    Magro, F.
    Heatta-Speicher, T.
    Michelena, N.
    Leitner, C.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I786 - I787
  • [36] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [37] Blood Pressure Control in Type 2 Diabetes
    Benck, Urs
    Krueger, Bernd
    Kraemer, Bernhard K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07): : 696 - 696
  • [38] Real-World Evidence Demonstrating The Association Of SGLT2 Inhibitors With Reduced Cardiovascular Disease In Patients With Type 2 Diabetes
    Wang, Wendy
    Chen, Lin Y.
    Walker, Rob
    Chow, Lisa
    Norby, Faye L.
    Alonso, Alvaro
    Pankow, Jim S.
    Lutsey, Pamela L.
    CIRCULATION, 2022, 145
  • [39] Real-World Evidence of Arabic Digital Therapeutics for People Living with Type 2 Diabetes in Qatar
    Jandali, Noor
    Saad, Rahma
    DIABETES, 2022, 71
  • [40] Review of real-world evidence studies in type 2 diabetes mellitus: Lack of good practices
    Lambert-Obry, Veronique
    Lafrance, Jean-Philippe
    Savoie, Michelle
    Henri, Sandrine
    Lachaine, Jean
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) : 372 - 379